健康系统生物库药物基因组学数据预测与预防不良药物事件的临床效用
本研究评估健康系统生物库中具有可干预药物基因组学结果的思者接受相关药物后不良事件发生率。在36,424例有PGx结果的患者中,HLA-A*31:01阳性者2327例(6.4%),HLA-B*15:02阳性者3543例(9.7%),TPMT中间代谢者2893例(7.9%),VKORC1 c.1639 G>A纯合者4249例(11.7%)。接受相关药物者中,HLA变异阳性者4.3%出现需停药皮疹,TPMT中间代谢者19.6%出现需停药严重骨髓抑制,VKORC1纯合者22.4%出现需停药或减量的活动性出血和/或INR>5。结论认为这些不良事件若在处方前获知PGx结果并配合临床决策支持可能得以预防。
要点
- 生物库PGx结果中可干预基因型频率较高,VKORC1纯合者达11.7%。
- TPMT中间代谢者用硫嘌呤时19.6%发生需停药严重骨髓抑制。
- VKORC1纯合者用华法林时22.4%发生需停药或减量的出血和/或INR>5。
核心结论
- 具有可干预PGx结果并接受相关药物的患者发生了可预测的不良药物事件,若处方前电子病历中有PGx结果及临床决策支持可能预防这些事件。
研究设计与样本
- 研究识别健康系统生物库中HLA-A*31:01、HLA-B*15:02、TPMT和VKORC1四个基因有可干预PGx结果且符合CPIC指南的患者,回顾电子病历确定潜在可预防不良事件发生率。
主要发现
- 36,424例有PGx结果患者中,HLA-A*31:01阳性2327例(6.4%),HLA-B*15:02阳性3543例(9.7%),TPMT中间代谢者2893例(7.9%),VKORC1 c.1639 G>A纯合者4249例(11.7%)。
- HLA变异阳性者接受卡马西平或奥卡西平(n=92)中4例(4.3%)出现需停药皮疹。
- TPMT中间代谢者接受硫嘌呤(n=56)中11例(19.6%)出现需停药严重骨髓抑制。
- VKORC1 c.1639 G>A纯合者接受华法林(n=379)中85例(22.4%)出现需停药或减量的活动性出血和/或INR>5。
关键数值与推荐
- HLA-A*31:01、HLA-B*15:02、TPMT和VKORC1为CPIC指南中有可干预推荐的基因。
- 相关药物包括卡马西平、奥卡西平、硫嘌呤和华法林。
临床怎么用
- 处方卡马西平、奥卡西平、硫嘌呤或华法林前应检索患者PGx结果并借助临床决策支持调整用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Medication-related harm represents a significant issue for patient safety and quality of care. One strategy to avoid preventable adverse drug events is to utilize patient-specific factors such as pharmacogenomics (PGx) to individualize therapy. OBJECTIVE: We measured the number of patients enrolled in a health-system biobank with actionable PGx results who received relevant medications and assessed the incidence of adverse drug events (ADEs) that might have been prevented had the PGx results been used to inform prescribing. METHODS: Patients with actionable PGx results in the following four genes with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines were identified: HLA-A*31:01, HLA-B*15:02, TPMT, and VKORC1. The patients who received interacting medications (carbamazepine, oxcarbazepine, thiopurines, or warfarin) were identified, and electronic health records were reviewed to determine the incidence of potentially preventable ADEs. RESULTS: Of 36,424 patients with PGx results, 2327 (6.4%) were HLA-A*31:01 positive; 3543 (9.7%) were HLA-B*15:02 positive; 2893 (7.9%) were TPMT intermediate metabolizers; and 4249 (11.7%) were homozygous for the VKORC1 c.1639 G>A variant. Among patients positive for one of the HLA variants who received carbamazepine or oxcarbazepine (n = 92), four (4.3%) experienced a rash that warranted drug discontinuation. Among the TPMT intermediate metabolizers who received a thiopurine (n = 56), 11 (19.6%) experienced severe myelosuppression that warranted drug discontinuation. Among patients homozygous for the VKORC1 c.1639 G>A variant who received warfarin (n = 379), 85 (22.4%) experienced active bleeding and/or international normalized ratio (INR) > 5 that warranted drug discontinuation or dose reduction. CONCLUSION: Patients with actionable PGx results from a health-system biobank who received relevant medications experienced predictable ADEs. These ADEs may have been prevented if the patients' PGx results were available in the electronic health record with clinical decision support prior to prescribing.
引用
- Shah SN, Gammal RS, Amato MG, et al. Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events. Drug Saf. 2021. PMID: 33620701. doi:10.1007/s40264-021-01050-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。